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Abstract
A recent collection of 213 imipenem-resistant Acinetobacter bau-
mannii (IRAB) clinical isolates was characterized for the presence
of acquired carbapenem-hydrolysing class D b-lactamases
(CHDLs) and clonality. A population structure analysis of IRAB
was also conducted, with ﬁve molecular typing methods. Three
main clusters, each one associated with a speciﬁc CHDL, were
observed with multilocus sequence typing. Overall, our results sug-
gest a switch in the dominant clone, with sequence type (ST) 92,
carrying blaOXA-23 (63.4%), replacing the closely related ST98,
carrying blaOXA-24/40 (22%). In addition, ST103, an independent
lineage, was associated with blaOXA-58-carrying isolates (14.6%).
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During the last decade, an ongoing rise in Acinetobacter
baumannii carbapenem resistance has been observed
worldwide, with recent reports of resistance to all available an-
timicrobials [1,2]. The production of acquired carbapenem-hy-
drolysing class D b-lactamases (CHDLs) belonging to the
OXA-23, OXA-24/40 and OXA-58 groups is the main
reported carbapenem resistance mechanism [1–7]. Despite the
description of two particular isolates producing IMP-5 [8] and,
more recently, OXA-23 [2], the imipenem resistance observed
in Portuguese A. baumannii clinical isolates has been mainly
associated with the production of OXA-24/40 and linked to
the spread of a particular multidrug-resistant clone [3,6].
Several sequence-based typing methods have been proposed
for A. baumannii population structure analyses [9–12], with
multilocus sequence typing (MLST) being increasingly applied as
a standard method [4,5,10,11,13]. Nevertheless, studies evalu-
ating the robustness of each particular method are still scarce.
In this work, we have characterized the antimicrobial sus-
ceptibility, acquired CHDLs and clonality of 213 previously
undescribed imipenem-resistant A. baumannii (IRAB) isolates,
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collected from 2004 to 2008, from ﬁve hospitals and two clini-
cal analysis laboratories located in the north and central
regions of Portugal. Isolates were identiﬁed with the Vitek 2
system and 16S rRNA gene sequencing. Susceptibility to b-
lactams, colistin and tigecycline was determined according to
CLSI guidelines [14]. The blaOXA genes were detected with a
multiplex PCR [7] and conﬁrmed by sequencing. The genetic
location of acquired CHDL genes was assessed by hybridiza-
tion of I-CeuI-digested genomic DNA with speciﬁc probes for
blaOXA-23, blaOXA-24/40, blaOXA-58 and 16S rRNA [6]. The vicin-
ity of each CHDL gene was established by PCR and sequenc-
ing [15–18]. Pulsed-ﬁeld gel electrophoresis (PFGE) typing
was performed with the ApaI restriction enzyme [3], and
pattern analysis was conducted with InfoQuestTM FP v5.4
(BioRad Laboratories, Hercules, CA, USA). Isolates clustering
together with >85% similarity levels [19] were considered to
belong to the same PFGE type. In order to better understand
the population structure of CHDL-producing IRAB Portugal,
we also used four distinct sequence-based typing methods
(Table 1). To this end, we selected nine representative iso-
lates (from the 213 IRAB isolates described above), together
with four additional isolates from a previously characterized
collection [3,6]. This selection process was aimed at simulta-
neously gathering isolates with different acquired CHDL con-
tent and of distinct PFGE types, collected from different
hospitals over the course of several years. Identiﬁcation of
PCR-based sequence groups (SGs) and sequence-based typing
of blaOXA-51-like genes were performed as described else-
where [9,12]. MLST analysis was conducted according to two
distinct schemes that will be referred to from now on as
MLST1 (developed by Bartual et al. [10]) and MLST2 (pub-
lished by Nemec et al. [11]). Clonal complexes (CCs) for
MLST1 were determined with the eBURST software program
(http://eburst.mlst.net/) [20]. It is important to point out the
renumbering of alleles, sequence types (STs) and CCs that
occurred on the MLST1 database in February 2010. CCs relat-
ing to MLST2 were deduced with a minimum spanning tree
analysis [13].
The majority of isolates (77.5%) were obtained from inpa-
tients attending a general hospital (hospital A), with an ende-
mic situation for IRAB, continuously observed since 2001
and epidemiologically monitored by our group [3,6]. The
remaining isolates were provided by four hospitals in which
IRAB had started to spread more recently (Table 1). Two
isolates collected from distinct outpatients, with no previous
hospitalization history, were obtained from two clinical
analysis laboratories. A predominance of blaOXA-23 has
been observed since 2006, being detected in 135 isolates
(63.4%) from four hospitals and from two outpatients; this
represents, to our knowledge, the ﬁrst description of T
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blaOXA-23-producing A. baumannii within the community.
Overall, besides resistance to all tested b-lactams, including
carbapenems, they had higher tigecycline MICs (Table 1),
ﬁndings that might explain their dominance. In fact, one iso-
late even showed an extreme drug resistance phenotype [2].
All OXA-23-producing isolates showed the association of
blaOXA-23 with Tn2006, with a chromosomal location. The
blaOXA-24/40 gene was detected in 47 isolates (22%) from
two hospitals. This acquired CHDL gene was encoded in
plasmids, ﬂanked by XerC/XerD-like binding sites [18] and,
for some isolates, it was also observed on the chromosome
(Gross. F, Quinteila S, Peixe L, unpublished data). The
blaOXA-58 gene was detected in 31 isolates (14.6%) obtained
from hospital A. The higher susceptibility generally shown by
these isolates, namely to meropenem and tigecycline, might
explain their low prevalence. The blaOXA-58 gene was ﬂanked
by ISAba3-like and ISAba3 elements upstream and down-
stream, respectively, and was found to be both chromosomal
and plasmid-carried. The insertion sequence ISAba1 was
observed upstream of blaOXA-51-like in all isolates. Only
three PFGE types were identiﬁed within this IRAB popula-
tion: PFGE type A for blaOXA-23-carrying and blaOXA-24/40-
carrying IRAB, and PFGE types B and C for blaOXA-58-carry-
ing IRAB (Table 1). Identiﬁcation of SGs showed that both
blaOXA-23-carrying and blaOXA-24/40-carrying IRAB isolates
belonged to SG1 [9], which corresponds to international clo-
ne II [13]. These isolates also harboured the same blaOXA-51-
like gene, blaOXA-66, and belonged to ST2 (CC2) as revealed
by the MLST2 scheme [11], suggesting a close relationship
between these two groups of isolates. The blaOXA-58-carrying
IRAB isolate belonged to SG4 [19], harboured blaOXA-132 as
a blaOXA-51-like allele, and belonged to ST15 according to
the MLST2 scheme. When the MLST1 scheme [10] was
applied, it was possible to observe a distinction between
blaOXA-23-carrying and blaOXA-24/40-carrying IRAB on the
basis of gpi and gyrB allelic variants. Thus, ST92 (the former
ST22) was identiﬁed for blaOXA-23-carrying IRAB, and a novel
ST, ST98 (formerly designated ST33, and double-locus vari-
ant of ST92) was identiﬁed for blaOXA-24/40-carrying IRAB
(Table 1; Fig. 1). These STs were included together in the
CC92
(1, 3, 3, 2, 2, 7, 3)
(1, 12, 3, 2, 2, 3, 3)
(12,17,12, 1, 29, 39, 19)
FIG. 1. Clustering of Acinetobacter baumannii sequence types (STs) by eBurst, with 185 multilocus sequence typing proﬁles representing 304 iso-
lates from the database (http://pubmlst.org/abaumannii/, last accessed 30 July 2010). Each ST is represented as a node; the relative size of each
node is indicative of its prevalence among the isolates, and lines connect single-locus variants. Clonal complex (CC)92 is represented by a dashed
circle. STs and the corresponding allelic proﬁles for the 13 isolates included in the population structure study are indicated by arrows.
CMI Research Notes 1277
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1262–1282
worldwide predominant CC92, with 20 recognized STs,
ST92 being the most frequently reported and disseminated
[4,5] (http://pubmlst.org/abaumannii/). The available data indi-
cate that most of the bla-OXA-23-carrying IRAB isolates clus-
ter with ST92 [4,5], and are usually associated with
multidrug resistance patterns, including reports of extreme
drug resistance [1]. On the other hand, ST98 seems to be
associated only with blaOXA-24/40-carrying IRAB from Portugal
(http://pubmlst.org/abaumannii/). Moreover, with this MLST1
scheme, blaOXA-58-carrying IRAB isolates were associated
with ST103 (formerly designated ST38), a lineage with no
apparent relationship with CC92 (Table 1; Fig. 1).
In summary, our results show the current dominance of
the worldwide ST92 carrying blaOXA-23. It seems interesting
to highlight the progressive switching that occurred in our
country, as shown by the MLST1 scheme, where ST98 IRAB
carrying blaOXA-24/40 has been gradually replaced by ST92
IRAB carrying blaOXA-23. This lineage, which exhibits an
extensive multidrug resistance proﬁle, is now emerging in
hospitals that have never before experienced the occurrence
of IRAB. It is well known that the association of CHDL
genes with mobile genetic elements favours transference
between different lineages. Curiously, we observed stability
of a speciﬁc acquired CHDL within each lineage. Although
both MLST schemes have been applied to differentiate
A. baumannii populations [4,5,10,11,13], our data point to the
higher resolution of the MLST1 scheme, which provided a
better association between epidemiological features, acquired
CHDL content and temporal distribution of the studied iso-
lates. It is reasonable to suggest that this MLST scheme
could emerge as a key epidemiological tool for future studies
of the regional and global epidemiology of A. baumannii.
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Multiple ST clonal complexes, with a
predominance of ST131, of Escherichia coli
harbouring blaCTX-M-15 in a tertiary hospital
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Abstract
The molecular epidemiology of 32 non-duplicate, CTX-M-15
extended-spectrum beta-lactamase (ESBL)-producing Escherichia
coli strains, isolated from clinical samples, was investigated. Mul-
tilocus sequence typing revealed multiple sequence type clonal
complexes: ST131 (12), ST405 (4), ST638 (3), ST38 (2), ST827
(2), ST224 (1), ST648 (1), ST46 (1) and two new sequence type
clonal complexes (1845 and 1848) in 22 pulsed ﬁeld gel electro-
phoresis clusters. The blaCTX-M-15 gene was located on conjuga-
tive IncF plasmids. This is the ﬁrst report of the worldwide
emerging clonal complex ST131 linked to blaCTX-M-15 in Tanzania
and demonstrates the need for constant surveillance in develop-
ing countries to prevent the spread of these multiresistant iso-
lates.
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Extended-spectrum beta-lactamases (ESBLs) are the predomi-
nant resistance enzymes among enterobacteriaceae and most
of the beta-lactamases described to date are plasmid-encoded
enzymes [1,2]. CTX-M is a recently described family of
ESBLs. These enzymes hydrolyze cefotaxime more effectively
than ceftazidime [3] and are also able to hydrolyze cefepime
with high efﬁciency. The blaCTX-M-15 allele is considered to be
the predominant allele worldwide [4,5]. Extensive studies
investigating the association of the multilocus sequence typing
(MLST) clonal complex ST131 and blaCTX-M-15 have been
reported from Canada, India, Kuwait, France, Switzerland,
Portugal, Spain, Korea and Japan; worldwide dissemination of
blaCTX-M-15 seems to be linked to this clonal complex, which
is situated in the phylogenetic group B2 [4,5].
Two studies revealed that CTX-M enzymes were present
among Enterobacteriaceae in a few isolates in Tanzania [6,7].
However, no study has investigated molecular characteristics
of Escherichia coli ESBL-producing isolates in detail from this
region of the world. For the ﬁrst time we report the
existence of the ST131 and multiple other sequence type
(ST) clones carrying blaCTX-M-15 in a single tertiary hospital in
Tanzania, East Africa.
A total of 32 consecutive antimicrobial-resistant Escherichia
coli clinical isolates were recovered from various wards and
clinics in a tertiary hospital in Tanzania. Of these, 27 were
from inpatients who had been on the ward for more than
72 h when the specimens were collected, whereas ﬁve
strains were obtained from outpatients. Strains were identi-
ﬁed as E. coli using in-house biochemical proﬁles [8]. Sus-
ceptibility patterns to ampicillin, amoxicillin/clavulanic acid,
sulphamethaxazole/trimethoprim, tetracycline, gentamicin,
ciproﬂoxacin, ceftriaxone, cefotaxime, cefepime and merope-
nem were determined by disk diffusion [9]; a disk synergy
test was performed to detect ESBL production [8]. Escherichi-
a coli ATCC 25922 was used as the quality control strain.
PCR ampliﬁcation of bla genes (blaTEM, blaSHV and blaCTX-M)
was performed using primers and methods described previ-
ously [10]. All PCR products were sequenced (LGC genom-
ics GmbH, Berlin, Germany) and the resulting sequences
were compared with known sequences using DNASTAR soft-
ware (DNASTAR Inc, Madison, WI, USA) and the Basic
Local Alignment Search Tool (BLAST, National Center for
Biotechnology Information, Bethesda, MA, USA).
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